Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis

Molina-Tijeras, José Alberto; Diez-Echave, Patrícia; Vezza, Teresa; Hidalgo-García, Laura; Ruiz-Malagón, Antonio Jesús; Rodríguez-Sojo, María Jesús; Romero, Miguel; Robles-Vera, Iñaki; García, Féderico; Plaza‐Díaz, Julio; Olivares, Mónica; Duarte, Juan; Rodríguez-Cabezas, Maria Elena; Rodríguez-Nogales, Alba; Gálvez, Júlio

doi:10.1016/j.phrs.2021.105471

Cited by 50 publications

(58 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, bacterial components, like LPS, could reach systemic circulation and provoke metabolic endotoxemia [122]. It has been confirmed these observations, since obese mice displayed reduced expression of the colonic markers of epithelial integrity as well as increased LPS plasma levels and upregulated expression of Tlr-4 in liver, fat, and aorta [114]. Importantly, L. fermentum CECT5716 significantly increased the colonic expression of the different markers involved in gut integrity in obese mice, thus restoring the intestinal barrier function and preventing bacterial components translocation, since it reduced LPS plasma levels and downregulated Tlr-4 expression [114].…”

mentioning

confidence: 74%

“…Interestingly, L. fermentum CECT5716 treatment reduced vascular expression of the pro-inflammatory cytokines Tnf-α and Il-1β in obese mice, as well as inhibited the increased NADPH activity in the aortic tissue. This suggests a reduction in ROS production and a higher NO bioavailability, which could promote the restoration of the impaired endothelium-dependent relaxation to acetylcholine [114]. It is well described that the gut plays an important role in the pathogenesis of obesity.…”

mentioning

confidence: 91%

“…Recently, L. fermentum CECT5716 has been evaluated in a model of high-fat diet (HFD)induced obesity in mice [114] (Table 4). This is very interesting since obesity is one of the main features of metabolic syndrome.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights

et al. 2021

Self Cite

View full text Add to dashboard Cite

Probiotics microorganisms exert their health-associated activities through some of the following general actions: competitive exclusion, enhancement of intestinal barrier function, production of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it has been described to possess potential beneficial effects on inflammatory processes and immunological alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory and immunomodulatory properties and elucidated the precise mechanisms of action involved in its beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on host health, mechanisms, and future therapeutic approaches.

show abstract

mentioning

confidence: 74%

mentioning

confidence: 91%

See 1 more Smart Citation

Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…As regards to metabolic abnormalities, L. fermentum alleviated inflammation and intestinal barrier integrity dysfunction, as well as improved insulin sensitivity in diet-and streptozotocin-induced diabetes in rats [64]. In other studies, L. fermentum CECT5716 exerted anti-obesity effects, associated with its anti-inflammatory properties and ameliorated endothelial dysfunction and gut dysbiosis in a model of high-fat diet (HFD)-induced obesity in mice [65]; and L. fermentum CRL1446 administration improved adiposity index, inflammatory, oxidative, glucose and lipid profiles and favourably modulated intestinal microbiota in mice with MetS [66]. Similarly, the administration of B. animalis subsp.…”

Section: Probiotics In Experimental Studiesmentioning

confidence: 90%

Probiotics as a Treatment for “Metabolic Depression”? A Rationale for Future Studies

Gawlik-Kotelnicka

Strzelecki

2021

Pharmaceuticals

View full text Add to dashboard Cite

Depression and metabolic diseases often coexist, having several features in common, e.g., chronic low-grade inflammation and intestinal dysbiosis. Different microbiota interventions have been proposed to be used as a treatment for these disorders. In the paper, we review the efficacy of probiotics in depressive disorders, obesity, metabolic syndrome and its liver equivalent based on the published experimental studies, clinical trials and meta-analyses. Probiotics seem to be effective in reducing depressive symptoms when administered in addition to antidepressants. Additionally, probiotics intake may ameliorate some of the clinical components of metabolic diseases. However, standardized methodology regarding probiotics use in clinical trials has not been established yet. In this narrative review, we discuss current knowledge on the recently used methodology with its strengths and limitations and propose criteria that may be implemented to create a new study of the effectiveness of probiotics in depressive disorders comorbid with metabolic abnormalities. We put across our choice on type of study population, probiotics genus, strains, dosages and formulations, intervention period, as well as primary and secondary outcome measures.

show abstract

“…Intestinal Lactobacillus and Bifidobacterium colonies increased whereas Escherichia coli colonies decreased. L. fermentum strains can effectively inhibit HFD-induced obesity through modulation of the PPAR-α signaling pathway, oxidative phosphorylation in adipose tissue, and gut microbiome (122)(123)(124). L. fermentum CECT5716 can also restore vascular redox status and improve eNOS coupling to prevent hypertension and endothelial dysfunction caused by tacrolimus (125).…”

Section: Lactobacillus Fermentummentioning

confidence: 99%

Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota

et al. 2021

View full text Add to dashboard Cite

The occurrence and development of cardiovascular-related diseases are associated with structural and functional changes in gut microbiota (GM). The accumulation of beneficial gut commensals contributes to the improvement of cardiovascular-related diseases. The cardiovascular-related diseases that can be relieved by Lactobacillus supplementation, including hypercholesterolemia, atherosclerosis, myocardial infarction, heart failure, type 2 diabetes mellitus, and obesity, have expanded. As probiotics, lactobacilli occupy a substantial part of the GM and play important functional roles through various GM-derived metabolites. Lactobacilli ultimately have a beneficial impact on lipid metabolism, inflammatory factors, and oxidative stress to relieve the symptoms of cardiovascular-related diseases. However, the axis and cellular process of gut commensal Lactobacillus in improving cardiovascular-related diseases have not been fully elucidated. Additionally, Lactobacillus strains produce diverse antimicrobial peptides, which help maintain intestinal homeostasis and ameliorate cardiovascular-related diseases. These strains are a field that needs to be further investigated immediately. Thus, this review demonstrated the mechanisms and summarized the evidence of the benefit of Lactobacillus strain supplementation from animal studies and human clinical trials. We also highlighted a broad range of lactobacilli candidates with therapeutic capability by mining their metabolites. Our study provides instruction in the development of lactobacilli as a functional food to improve cardiovascular-related diseases.

show abstract

Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis

Cited by 50 publications

References 66 publications

Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights

Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights

Probiotics as a Treatment for “Metabolic Depression”? A Rationale for Future Studies

Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota

Contact Info

Product

Resources

About